Who are AstraZeneca's key investors?

Key investors in AstraZeneca include HHS Administration for Strategic Preparedness and Response.

How many employees does AstraZeneca have?

As of Sat, 25 Apr 2026, AstraZeneca has approximately 10,001+ employees employees.

How much website traffic does AstraZeneca receive?

AstraZeneca receives about 1.3M monthly website visits in the latest Datakart source snapshot. This helps benchmark market attention, demand generation, and digital reach.

Is AstraZeneca currently hiring?

AstraZeneca has 1.1K open roles in the latest source snapshot. Open job volume can indicate team expansion, budget movement, and active buying needs by department.

What technologies does AstraZeneca use?

AstraZeneca's detected technology footprint includes Rstudio, Relativity, Ethicspoint, Desigo Cc, Google Ai, Brandwatch. The full profile lists additional verified technologies when available.

Company profile

Pharmaceutical Manufacturing

AstraZeneca - Company Intelligence Profile

Industry: Pharmaceutical Manufacturing | Founded: not publicly disclosed | HQ: cambridge, United Kingdom

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.

Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for AstraZeneca to help teams evaluate the account with useful business context.

Public company

AstraZeneca

astrazeneca.com

Employees

79.2K

Monthly visits

1.3M

Open roles

1.1K

Search volume

33.1K

View intelligence Start free trial

Company Snapshot

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.

Community Guidelines: bit.ly/2MgAcio

N/A

Founded

79.2K

Employee count

1.3M

Monthly website visits

1.1K

Open roles

Company Snapshot Details

Legal name: AstraZeneca PLC

Headquarters: Cambridge, Cambridgeshire, United Kingdom

Industry: Pharmaceutical Manufacturing

Sub-sector: Pharmaceutical Manufacturing

Website: https://www.astrazeneca.com

YoY headcount growth: not publicly disclosed

Company stage: Public Company

Last updated: Sat, 25 Apr 2026

Company intelligence

Business signals that help qualify AstraZeneca

This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.

Source snapshot

Last refreshed 2026-04-25 | 33K search volume | Domain astrazeneca.com

Annual revenue

$57.2B

Reported annual revenue from the source dataset when available.

Quarterly revenue

$15.2B

Standalone quarterly revenue field from the source dataset.

Monthly visits

1.3M

Latest monthly visits value available from the source dataset.

Global web rank

#45,962

Lower rank values indicate stronger web visibility in the source dataset.

Employees

79.2K

Latest employees value available from the source dataset.

Employee reviews

10.1K

Latest employee reviews value available from the source dataset.

-30 monthly (-2.6%)

Hiring demand

1.1K

Open roles reveal which teams may be expanding and where vendor demand can emerge. For AstraZeneca, this signal is based on the latest available source snapshot.

+435 monthly (+0.6%)

Headcount momentum

79.2K

Recent employee count movement helps qualify growth, contraction, and operational scale. For AstraZeneca, this signal is based on the latest available source snapshot.

+39.9K monthly (+1.1%)

Audience growth

3.8M

LinkedIn follower movement is a useful proxy for employer brand, market attention, and hiring reach. For AstraZeneca, this signal is based on the latest available source snapshot.

-34.3K monthly (-2.6%)

Web demand

1.3M

Website traffic movement helps benchmark customer interest and go-to-market momentum. For AstraZeneca, this signal is based on the latest available source snapshot.

0 quarterly

Employee sentiment

4.0

Employee review movement can surface internal confidence, culture stability, and retention risk. For AstraZeneca, this signal is based on the latest available source snapshot.

Identity atlas

AstraZeneca identity, aliases, ownership, and taxonomy

This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.

Company descriptions

All available company description fields from the source dataset.

Company descriptiondescription

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio

Enriched descriptionDescription Enriched

AstraZeneca is a research-based biopharmaceutical company that is a global, science-led biopharmaceutical business. They are used by millions of patients worldwide.

Metadata descriptionDescription Metadata Raw

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

LinkedIn followers

3.8M

Latest linkedin followers value available from the source dataset.

Owler followers

20.5K

Latest owler followers value available from the source dataset.

Technologies detected

1.2K

Latest technologies detected value available from the source dataset.

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Yes

Is Public

Aliases and domain variants

Company name aliases, website aliases, and canonical domain signals.

Company alias

astrazeneca

Company Name Alias

Company alias

astrazeneca uk limited

Company Name Alias

Company alias

astrazeneca plc

Company Name Alias

Website alias

https://www.astrazeneca.com

Website Alias

Website alias

https://www.astrazeneca.com/

Website Alias

Canonical website

https://www.astrazeneca.com

website

Website domain

astrazeneca.com

Website Domain

Unique website

Yes

Unique Website

Unique domain

Yes

Unique Domain

Expired domain

Expired Domain

LinkedIn shorthand

astrazeneca

Canonical LinkedIn Shorthand Name

Source ID

1603

Source ID

UUID

24C84BHHA0GEWHFJ65W2EK09DE

uuid

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

['biopharmaceutical', 'pharmaceutical', 'innovation', 'research and development', 'global business', 'global', 'patients', 'innovative medicines', 'research-based', 'health', 'biotech', 'clinical-research', 'drug-development', 'oncology', 'pharma', 'biopharma', 'biotechnology', 'health care', 'medical', 'precision medicine']

Categories And Keywords

Social follower counts

Follower counts available across LinkedIn, Twitter, and Owler.

LinkedIn followers

3.8M

Followers Count LinkedIn

Owler followers

20.5K

Followers Count Owler

Company locations

Known company locations and office addresses.

Primary location

1 Francis Crick Avenue; Cambridge Biomedical Campus; Cambridge, Cambridgeshire CB2 0AA, GB

Office location

Astraallen; Sodertalje, Stockholm County 152 57, SE

Office location

1 Francis Crick Ave; Cambridge, England, United Kingdom

Office location

1 Francis Crick Avenue; Cambridge, CB2 0AA, United Kingdom

Office location

Cambridge, Cambridgeshire, United Kingdom

Social profiles

Official and source-linked social profiles.

Website

https://www.astrazeneca.com

https://uk.linkedin.com/company/astrazeneca

Crunchbase

https://www.crunchbase.com/organization/astrazeneca

Facebook

https://www.facebook.com/astrazeneca

Twitter / X

https://www.twitter.com/astrazeneca

Instagram

https://www.instagram.com/astrazeneca

YouTube

https://www.youtube.com/user/astrazeneca

Company contact points

Public company-level contact points available in the source dataset.

Phone

44-20-3749-5000

Phone

+44 20 3749 5000

Financial intelligence

AstraZeneca revenue, funding, IPO, and acquisition history

Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.

Annual revenue

$57.2B

Reported annual revenue from the source dataset when available.

Quarterly revenue

$15.2B

Standalone quarterly revenue field from the source dataset.

Revenue range

$10B+

Reported annual revenue band from the source dataset.

Total disclosed funding

$9.4B

Sum of disclosed funding round amounts available in the source dataset.

Funding rounds

Number of funding rounds captured in the source dataset.

Acquisitions captured

120

Number of acquisition records captured across the available source columns.

Revenue signals

Annual, quarterly, and range-based revenue signals available in the source dataset.

Source 5

$57.2B

Annual revenue

Source 1$58.7B

Source 4$10B+

Standalone quarterly revenue$15.2B

IPO and stock listing

IPO date, share price, exchange tickers, and public market identifiers.

IPO date

1998-02-01

IPO Date

Stock tickerAZN.L

Stock tickerAZN

Latest closing priceGBP 115.34

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Yes

Is Public

Income statement rows

Income statement rows with revenue and profitability metrics where available.

FY, 2025

Fiscal Year

Primary value

Revenue: $58.7B

Additional metrics

Gross profit: $54.2B; EBITDA: $19.3B; EBIT: $13.7B; Net income: $10.2B; Operating expense: $34.9B; Gross margin: 92.3%; EBITDA margin: 32.9%

Q3, 2025

Primary value

Revenue: $15.2B

Additional metrics

Gross profit: $14B; EBITDA: $5.1B; EBIT: $3.6B; Net income: $2.5B; Operating expense: $8.9B; Gross margin: 92.3%; EBITDA margin: 33.6%

Q2, 2025

Primary value

Revenue: $14.5B

Additional metrics

Gross profit: $13.5B; EBITDA: $4.9B; EBIT: $3.5B; Net income: $2.4B; Operating expense: $8.6B; Gross margin: 93.0%; EBITDA margin: 33.7%

Q1, 2025

Primary value

Revenue: $13.6B

Additional metrics

Gross profit: $12.7B; EBITDA: $4.9B; EBIT: $3.7B; Net income: $2.9B; Operating expense: $7.9B; Gross margin: 93.8%; EBITDA margin: 36.0%

FY, 2024

Fiscal Year

Primary value

Revenue: $54.1B

Additional metrics

Gross profit: $45.4B; EBITDA: $16.6B; EBIT: $10B; Net income: $7B; Operating expense: $28.8B; Gross margin: 84.0%; EBITDA margin: 30.7%

Q3, 2024

Primary value

Revenue: $13.6B

Additional metrics

Gross profit: $12.3B; EBITDA: $3.9B; EBIT: $2.1B; Net income: $1.4B; Operating expense: $8.4B; Gross margin: 90.9%; EBITDA margin: 28.8%

Q2, 2024

Primary value

Revenue: $12.9B

Additional metrics

Gross profit: $12.1B; EBITDA: $4B; EBIT: $2.7B; Net income: $1.9B; Operating expense: $8.1B; Gross margin: 93.5%; EBITDA margin: 30.9%

Q1, 2024

Primary value

Revenue: $12.7B

Additional metrics

Gross profit: $11.8B; EBITDA: $4.4B; EBIT: $3.1B; Net income: $2.2B; Operating expense: $7.4B; Gross margin: 92.9%; EBITDA margin: 34.4%

FY, 2023

Fiscal Year

Primary value

Revenue: $45.8B

Additional metrics

Gross profit: $39.8B; EBITDA: $13.3B; EBIT: $8.2B; Net income: $6B; Operating expense: $26.5B; Gross margin: 86.9%; EBITDA margin: 29.0%

Q3, 2023

Primary value

Revenue: $11.5B

Additional metrics

Gross profit: $10.7B; EBITDA: $3B; EBIT: $1.9B; Net income: $1.4B; Operating expense: $7.8B; Gross margin: 93.5%; EBITDA margin: 25.9%

Q2, 2023

Primary value

Revenue: $11.4B

Additional metrics

Gross profit: $11.5B; EBITDA: $4B; EBIT: $2.5B; Net income: $1.8B; Operating expense: $7.5B; Gross margin: 1.0%; EBITDA margin: 34.9%

Q1, 2023

Primary value

Revenue: $10.9B

Additional metrics

Gross profit: $10.9B; EBITDA: $3.8B; EBIT: $2.5B; Net income: $1.8B; Operating expense: $7.1B; Gross margin: 99.8%; EBITDA margin: 34.9%

Period	Primary value	Additional metrics
FY, 2025 Fiscal Year	Revenue: $58.7B	Gross profit: $54.2B; EBITDA: $19.3B; EBIT: $13.7B; Net income: $10.2B; Operating expense: $34.9B; Gross margin: 92.3%; EBITDA margin: 32.9%
Q3, 2025 Q3	Revenue: $15.2B	Gross profit: $14B; EBITDA: $5.1B; EBIT: $3.6B; Net income: $2.5B; Operating expense: $8.9B; Gross margin: 92.3%; EBITDA margin: 33.6%
Q2, 2025 Q2	Revenue: $14.5B	Gross profit: $13.5B; EBITDA: $4.9B; EBIT: $3.5B; Net income: $2.4B; Operating expense: $8.6B; Gross margin: 93.0%; EBITDA margin: 33.7%
Q1, 2025 Q1	Revenue: $13.6B	Gross profit: $12.7B; EBITDA: $4.9B; EBIT: $3.7B; Net income: $2.9B; Operating expense: $7.9B; Gross margin: 93.8%; EBITDA margin: 36.0%
FY, 2024 Fiscal Year	Revenue: $54.1B	Gross profit: $45.4B; EBITDA: $16.6B; EBIT: $10B; Net income: $7B; Operating expense: $28.8B; Gross margin: 84.0%; EBITDA margin: 30.7%
Q3, 2024 Q3	Revenue: $13.6B	Gross profit: $12.3B; EBITDA: $3.9B; EBIT: $2.1B; Net income: $1.4B; Operating expense: $8.4B; Gross margin: 90.9%; EBITDA margin: 28.8%
Q2, 2024 Q2	Revenue: $12.9B	Gross profit: $12.1B; EBITDA: $4B; EBIT: $2.7B; Net income: $1.9B; Operating expense: $8.1B; Gross margin: 93.5%; EBITDA margin: 30.9%
Q1, 2024 Q1	Revenue: $12.7B	Gross profit: $11.8B; EBITDA: $4.4B; EBIT: $3.1B; Net income: $2.2B; Operating expense: $7.4B; Gross margin: 92.9%; EBITDA margin: 34.4%
FY, 2023 Fiscal Year	Revenue: $45.8B	Gross profit: $39.8B; EBITDA: $13.3B; EBIT: $8.2B; Net income: $6B; Operating expense: $26.5B; Gross margin: 86.9%; EBITDA margin: 29.0%
Q3, 2023 Q3	Revenue: $11.5B	Gross profit: $10.7B; EBITDA: $3B; EBIT: $1.9B; Net income: $1.4B; Operating expense: $7.8B; Gross margin: 93.5%; EBITDA margin: 25.9%
Q2, 2023 Q2	Revenue: $11.4B	Gross profit: $11.5B; EBITDA: $4B; EBIT: $2.5B; Net income: $1.8B; Operating expense: $7.5B; Gross margin: 1.0%; EBITDA margin: 34.9%
Q1, 2023 Q1	Revenue: $10.9B	Gross profit: $10.9B; EBITDA: $3.8B; EBIT: $2.5B; Net income: $1.8B; Operating expense: $7.1B; Gross margin: 99.8%; EBITDA margin: 34.9%

Funding rounds

Funding history and recent round context.

Post-IPO Debt

$2B

2026-02-01

Post-IPO Debt

$1.5B

2024-07-30

Post-IPO Debt

$2.2B

2023-02-28

Post-IPO Debt

$1.5B

2023-02-24

Grant

$1.6B

2020-10-01

Grant

$486M

2020-10-01 | HHS Administration for Strategic Preparedness and Response

Grant

$23.6M

2020-06-01

Post-IPO Equity

2001-05-01

Post-IPO Debt

Acquisitions and corporate activity

Acquisitions and corporate activity captured in the source dataset.

Modella AI, Inc

Acquisition

2026-01-01 | Acquisition List Source 5

SixPeaks Bio AG

$170M

2025-10-01 | Acquisition List Source 5

EsoBiotec

$1B

2025-03-17 | Acquisition List Source 2

EsoBiotec B.V.

$999.5M

2025-03-01 | Acquisition List Source 5

FibroGen China

$160M

2025-02-20 | Acquisition List Source 2

FibroGen China

$160M

2025-02-01 | Acquisition List Source 5

Amolyt Pharma

Acquisition

2024-07-15 | Acquisition List Source 1

Fusion Pharmaceuticals

Acquisition

2024-06-04 | Acquisition List Source 1

Fusion Pharmaceuticals

$2.4B

2024-03-19 | Acquisition List Source 2

Amolyt Pharma

$1.1B

2024-03-14 | Acquisition List Source 2

Amolyt Pharma SAS

$800M

2024-03-01 | Acquisition List Source 5

Fusion Pharmaceuticals, Inc.

$2B

2024-03-01 | Acquisition List Source 5

Gracell Biotechnologies

Acquisition

2024-02-22 | Acquisition List Source 1

Icosavax

Acquisition

2024-02-19 | Acquisition List Source 1

Icosavax

$1.1B

2023-12-12 | Acquisition List Source 2

Icosavax, Inc.

$1.1B

2023-12-01 | Acquisition List Source 5

Gracell Biotechnologies Inc.

$1.2B

2023-12-01 | Acquisition List Source 5

Pfizer’s Early-stage Rare Disease Gene Therapy Portfolio

$1B

2023-07-01 | Acquisition List Source 5

CinCor Pharma

$1.3B

2023-02-24 | Acquisition List Source 1

Neogene Therapeutics

$120M

2023-01-16 | Acquisition List Source 1

CinCor Pharma

$1.8B

2023-01-09 | Acquisition List Source 2

Neogene Therapeutics

$320M

2022-11-29 | Acquisition List Source 2

LogicBio Therapeutics

$72M

2022-11-16 | Acquisition List Source 1

TeneoTwo

$100M

2022-08-11 | Acquisition List Source 1

TeneoTwo

$100M

2022-07-05 | Acquisition List Source 2

Caelum Biosciences

$500M

2021-10-06 | Acquisition List Source 1

Caelum Biosciences

$500M

2021-09-29 | Acquisition List Source 2

Alexion Pharmaceuticals

$39B

2020-12-12 | Acquisition List Source 1

Takeda Respiratory Business

$575M

2016-05-10 | Acquisition List Source 1

AcertaPharma

$4B

2015-12-17 | Acquisition List Source 1

ZS Pharma

$2.7B

2015-11-06 | Acquisition List Source 1

Almirall

Acquisition

2014-07-30 | Acquisition List Source 1

Pearl Therapeutics

$1.2B

2013-06-10 | Acquisition List Source 1

Omthera Pharmaceuticals

$323M

2013-05-29 | Acquisition List Source 1

Ardea Biosciences

$781M

2012-04-23 | Acquisition List Source 1

Guangdong BeiKang Pharmaceutical Company Ltd

Acquisition

2011-12-08 | Acquisition List Source 1

Novexel

Acquisition

2009-12-23 | Acquisition List Source 1

Arrow Therapeutics

$150M

2007-02-01 | Acquisition List Source 1

Cambridge Antibody Technology

Acquisition

2006-05-18 | Acquisition List Source 1

KuDOS Pharmaceuticals Ltd

Acquisition

2005-12-23 | Acquisition List Source 1

Alexion Pharma Argentina SRL

Acquisition

Acquisition List Source 1

Alexion Serviços e Farmacêutica do Brasil Ltda.

Acquisition

Acquisition List Source 1

AstraZeneca Asia-Pacific Business Services Sdn Bhd

Acquisition

Acquisition List Source 1

AstraZeneca Nijmegen B.V.

Acquisition

Acquisition List Source 1

AstraZeneca China UK Limited

Acquisition

Acquisition List Source 1

Novastuart Produtos Farmacêuticos Lda

Acquisition

Acquisition List Source 1

AstraZeneca K.K.

Acquisition

Acquisition List Source 1

Alexion Bermuda Limited

Acquisition

Acquisition List Source 1

AstraZeneca Pharmaceutical (China) Co. Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Taiwan Limited

Acquisition

Acquisition List Source 1

Spirogen Sar

Acquisition

Acquisition List Source 1

AstraZeneca Share Trust Limited

Acquisition

Acquisition List Source 1

Alexion Pharma Middle East FZ-LLC

Acquisition

Acquisition List Source 1

AstraZeneca Holdings Pty Limited

Acquisition

Acquisition List Source 1

AstraZeneca Pharmaceutical (Chengdu) Co., Ltd

Acquisition

Acquisition List Source 1

KuDOS Pharmaceuticals Limited

Acquisition

Acquisition List Source 1

Fundación AstraZeneca

Acquisition

Acquisition List Source 1

AstraZeneca Jota B.V.

Acquisition

Acquisition List Source 1

AstraZeneca Computational Pathology GmbH

Acquisition

Acquisition List Source 1

AstraZeneca Dunkerque Production SCS

Acquisition

Acquisition List Source 1

Alexion Pharma Spain S.L

Acquisition

Acquisition List Source 1

Alexion Pharma Italy Srl

Acquisition

Acquisition List Source 1

AstraZeneca Pharma Poland Sp.z.o.o.

Acquisition

Acquisition List Source 1

Alexion Pharma Germany GmbH

Acquisition

Acquisition List Source 1

AstraZeneca Kft

Acquisition

Acquisition List Source 1

AZENCO4 Limited

Acquisition

Acquisition List Source 1

AstraZeneca Farmaceutica Holding Spain, S.A.

Acquisition

Acquisition List Source 1

AstraZeneca AB

Acquisition

Acquisition List Source 1

WuXi MedImmune Biopharmaceutical Co., Limited

Acquisition

Acquisition List Source 1

AstraZeneca Treasury B.V.

Acquisition

Acquisition List Source 1

AstraZeneca Investment (China) Co., Ltd

Acquisition

Acquisition List Source 1

Zeneca Finance (Netherlands) Company

Acquisition

Acquisition List Source 1

AstraZeneca Pharmaceutical (Qingdao) Co., Ltd

Acquisition

Acquisition List Source 1

KuDOS Horsham Limited

Acquisition

Acquisition List Source 1

AstraZeneca Ilac Sanayi ve Ticaret Limited Sirket

Acquisition

Acquisition List Source 1

Portola Pharmaceuticals LLC

Acquisition

Acquisition List Source 1

AstraZeneca Pharmaceutical (Beijing) Co., Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Treasury Limited

Acquisition

Acquisition List Source 1

AstraZeneca Korea Co. Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Pharma S.R.L.

Acquisition

Acquisition List Source 1

Alexion US Holdings LLC

Acquisition

Acquisition List Source 1

AstraZeneca Investments Limited

Acquisition

Acquisition List Source 1

Alexion Pharma OOO LLC

Acquisition

Acquisition List Source 1

AstraZeneca CAMCAR, S.A.

Acquisition

Acquisition List Source 1

AstraZeneca (Israel) Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Holdings B.V.

Acquisition

Acquisition List Source 1

AstraZeneca Eesti OÜ

Acquisition

Acquisition List Source 1

AstraZeneca (Guangzhou) Pharmaceutical Co., Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Sdn Bhd

Acquisition

Acquisition List Source 1

AstraZeneca Hong Kong Limited

Acquisition

Acquisition List Source 1

AstraZeneca d.o.o.

Acquisition

Acquisition List Source 1

MedImmune U.K. Limited

Acquisition

Acquisition List Source 1

Evinova AG

Acquisition

Acquisition List Source 1

AstraZeneca Continent

Acquisition

Acquisition List Source 1

Astra Export & Trading Aktiebolag

Acquisition

Acquisition List Source 1

TeneoTwo, Inc.

Acquisition

Acquisition List Source 1

AstraZeneca Nominees Limited

Acquisition

Acquisition List Source 1

AstraZeneca Industries, LLC

Acquisition

Acquisition List Source 1

AstraZeneca Limited

Acquisition

Acquisition List Source 1

AstraZeneca (Thailand) Limited

Acquisition

Acquisition List Source 1

Alexion Europe SAS

Acquisition

Acquisition List Source 1

AstraZeneca Health Care Division, S.A. de C.V.

Acquisition

Acquisition List Source 1

AstraZeneca Farmaceutica Chile Limitada

Acquisition

Acquisition List Source 1

ZS Pharma Inc

Acquisition

Acquisition List Source 1

Achillion Pharmaceuticals Inc.

Acquisition

Acquisition List Source 1

AstraZeneca Maroc SARLAU

Acquisition

Acquisition List Source 1

AstraZeneca Investment Consulting (Wuxi) Co., Ltd

Acquisition

Acquisition List Source 1

AstraZeneca Pharmaceutical (Shanghai) Co., Ltd

Acquisition

Acquisition List Source 1

Grey Wolf Merger Sub

Acquisition

Acquisition List Source 1

Stuart Pharma Aktiebolag

Acquisition

Acquisition List Source 1

AstraZeneca GmbH

Acquisition

Acquisition List Source 1

Alexion Pharma GK

Acquisition

Acquisition List Source 1

Alexion Business Services Private Limited

Acquisition

Acquisition List Source 1

Simesa SpA

Acquisition

Acquisition List Source 1

AstraZeneca Venezuela S.A.

Acquisition

Acquisition List Source 1

AstraZeneca Employee Share Trust Limited

Acquisition

Acquisition List Source 1

AstraZeneca Latvija SIA

Acquisition

Acquisition List Source 1

AstraZeneca PTY Limited

Acquisition

Acquisition List Source 1

Modella AI

Acquisition

Acquisition List Source 2

SixPeaks Bio

Acquisition

Acquisition List Source 2

Audience analytics

Web visibility, demand, and topics

Use these signals to understand discoverability, demand quality, search interest, and audience fit.

Monthly visits

1.3M

Latest monthly visits value available from the source dataset.

Global web rank

#45,962

Lower rank values indicate stronger web visibility in the source dataset.

Bounce rate

40.0%

Latest bounce rate value available from the source dataset.

Pages per visit

2.79

Latest pages per visit value available from the source dataset.

Average visit duration

3m 1s

Latest average visit duration value available from the source dataset.

Estimated monthly page views

3.6M

Derived estimate calculated as monthly visits multiplied by pages per visit.

Website visits

Website visits trend from the latest source snapshots.

LinkedIn followers

LinkedIn followers trend from the latest source snapshots.

Website visits by country

United States27.35

United Kingdom14.52

Poland9.18

Japan6.35

Canada5.74

Employees, hiring, attrition, and compensation

This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.

Employees

79.2K

Latest employees value available from the source dataset.

Inferred employees

56.9K

Latest inferred employees value available from the source dataset.

Open roles

1.1K

Latest open roles value available from the source dataset.

Departures

Latest departures value available from the source dataset.

Employee attrition rate

0.0%

Latest employee attrition rate value available from the source dataset.

Hiring intensity

14.2 roles / 1K employees

Derived signal showing open roles normalized by employee count.

Employee headcount

Employee headcount trend from the latest source snapshots.

Inferred employees

Inferred employees trend from the latest source snapshots.

Open job postings

Open job postings trend from the latest source snapshots.

Employee attrition rate

Employee attrition rate trend from the latest source snapshots.

Employee count by department

Medical9K

Sales8.5K

Research8.3K

Other Department7.3K

Operations4.1K

Technical3.9K

Project Management3.6K

Employee count by seniority

Specialist20.4K

Manager10.7K

Other Management8.7K

Senior8.5K

Director7.9K

Head1.9K

Intern684

Employee count by region

Northern America14.8K

Northern Europe13K

Latin America5K

Southern Europe4.1K

Southern Asia4.1K

Eastern Europe3.9K

Western Europe3.3K

Top employee countries

United States13K

United Kingdom7.6K

Sweden4.7K

India4K

Poland2.6K

Spain2K

Mexico1.9K

Active job openings

Selected open roles that reveal current hiring demand.

Attaché Scientifique Hospitalier – Onco-Hématologie – Rhône-Alpes (H/F)

Open role

3660596602

Senior Director – Site IT APAC Region

Open role

4258811975

Automation Associate Principal SME

Open role

4258811995

（Sr）Medical Advisor -肿瘤/罕见病/呼吸

Open role

4258812933

MR-CVRM-威海

Open role

4258814765

MR-OC-宁波

Open role

4258814821

（Sr）Medical Advisor -肿瘤/罕见病/呼吸

Open role

4258817604

Associate Director, Physician (GU)

Open role

4258818531

Showing 8 of 18 available records.

Where employees came from

Common previous employers visible in employee profile movement.

GSK

3.3K employee movements

Internal profile link

Pfizer

3.1K employee movements

Internal profile link

Novartis

2.7K employee movements

Internal profile link

Sanofi

2.4K employee movements

Internal profile link

Bristol Myers Squibb

2.3K employee movements

Internal profile link

Roche

1.6K employee movements

Internal profile link

MedImmune

1.5K employee movements

Internal profile link

Boehringer Ingelheim

1.2K employee movements

Internal profile link

Showing 8 of 9 available records.

Where employees go next

Common next employers visible in employee profile movement.

Novartis

2.5K employee movements

Internal profile link

GSK

2.3K employee movements

Internal profile link

Sanofi

1.9K employee movements

Internal profile link

Pfizer

1.9K employee movements

Internal profile link

Roche

1.3K employee movements

Internal profile link

Boehringer Ingelheim

1.2K employee movements

Internal profile link

Novo Nordisk

1.1K employee movements

Internal profile link

Amgen

1K employee movements

Internal profile link

Showing 8 of 10 available records.

Base pay benchmarks

Selected base salary benchmarks from the source dataset.

Responsable accès au marché

EUR $118.5K

Annual | Updated 2024-09-23

visiteur médical

EUR $118.5K

Annual | Updated 2024-09-23

Global Clinical Solutions Specialist

PLN $90.2K

Monthly | Updated 2024-09-23

pharmacien affaires réglementaires

EUR $118.5K

Annual | Updated 2024-09-23

Therapy Area Specialist

GBP $50.8K

Annual | Updated 2024-09-20

Account Therapy Specialist

GBP $56.9K

Annual | Updated 2024-09-20

Senior Test Engineer

INR $610K

Annual | Updated 2024-09-18

Test Engineer

INR $548.8K

Annual | Updated 2024-09-18

Showing 8 of 10 available records.

Additional pay benchmarks

Selected bonus and additional compensation benchmarks.

pharmacien affaires réglementaires

Cash Bonus $13K; Stock Bonus $10K

Annual | Updated 2024-09-23

Responsable accès au marché

Cash Bonus $13K; Stock Bonus $10K

Annual | Updated 2024-09-23

visiteur médical

Cash Bonus $13K; Stock Bonus $10K

Annual | Updated 2024-09-23

Account Therapy Specialist

Commission Sharing $5.1K

Annual | Updated 2024-09-20

Therapy Area Specialist

Cash Bonus $10.9K

Annual | Updated 2024-09-20

Test Engineer

Cash Bonus $93.7K

Annual | Updated 2024-09-18

Laboratory Technician

Cash Bonus $1.4K

Annual | Updated 2024-09-13

Analista De Farmacovigilância Pleno

Cash Bonus $13K; Stock Bonus $10K

Monthly | Updated 2024-09-12

Showing 8 of 10 available records.

Total compensation benchmarks

Selected total compensation benchmarks from the source dataset.

pharmacien affaires réglementaires

EUR $141.5K

Annual | Updated 2024-09-23

Responsable accès au marché

EUR $141.5K

Annual | Updated 2024-09-23

visiteur médical

EUR $141.5K

Annual | Updated 2024-09-23

Global Clinical Solutions Specialist

PLN $90.2K

Monthly | Updated 2024-09-23

Therapy Area Specialist

GBP $57K

Annual | Updated 2024-09-20

Account Therapy Specialist

GBP $62K

Annual | Updated 2024-09-20

Test Engineer

INR $595.7K

Annual | Updated 2024-09-18

Senior Test Engineer

INR $610K

Annual | Updated 2024-09-18

Showing 8 of 10 available records.

Product and reputation

Product readiness, customer proof, and employee sentiment

Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.

Employee reviews

10.1K

Latest employee reviews value available from the source dataset.

Employee rating

4.0

Latest review score available from the source dataset.

Employee review distribution

Score 53.2K

Score 43.1K

Score 31.5K

Score 2593

Score 1402

Employee review score breakdown

Compensation Benefits4.1

Diversity Inclusion4.1

Culture Values3.9

Work Life Balance3.8

Career Opportunities3.7

Senior Management3.5

Ceo Approval88.0%

Product availability Q&A

Buyer-facing product availability signals in question-and-answer format.

Is pricing information available?

No. The source snapshot does not list pricing information for this company.

Source availability signal

Is a free trial listed?

No. The source snapshot does not list a free trial for this company.

Source availability signal

Can buyers request a demo?

No. The source snapshot does not list a demo motion for this company.

Source availability signal

Is the product downloadable?

No. The source snapshot does not list downloadable software for this company.

Source availability signal

Are mobile apps listed?

No. The source snapshot does not list mobile apps for this company.

Source availability signal

Is public documentation listed?

No. The source snapshot does not list public documentation for this company.

Source availability signal

Are online reviews listed?

No. The source snapshot does not list online reviews for this company.

Source availability signal

Company graph

Technology, leadership, competitors, funding, and corporate activity

These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.

Verified technologies

Detected tools and systems verified in the source dataset.

Rstudio

Verified technology